Ikena Oncology (NASDAQ:IKNA) Announces Earnings Results, Beats Expectations By $0.05 EPS

Ikena Oncology (NASDAQ:IKNA - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.05, Zacks reports.

Ikena Oncology Trading Down 2.1 %

Shares of IKNA stock traded down $0.03 during trading hours on Monday, reaching $1.41. 57,653 shares of the company's stock were exchanged, compared to its average volume of 199,378. Ikena Oncology has a 1 year low of $1.22 and a 1 year high of $1.94. The stock has a market cap of $68.04 million, a PE ratio of -1.15 and a beta of 0.49. The stock's fifty day moving average price is $1.49 and its two-hundred day moving average price is $1.62.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on IKNA. HC Wainwright restated a "buy" rating and issued a $4.00 price objective on shares of Ikena Oncology in a report on Monday, November 11th. Wedbush restated a "neutral" rating and issued a $2.00 price target on shares of Ikena Oncology in a report on Monday, December 23rd.

Ikena Oncology Company Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.